Unraveling the Differences of the Hydrolytic Activity of Trypanosoma cruzi trans-Sialidase and Trypanosoma rangeli Sialidase: A Quantum Mechanics–Molecular Mechanics Modeling Study

Chagas’ disease, also known as American trypanosomiasis, is a lethal, chronic disease that currently affects more than 10 million people in Central and South America. The trans-sialidase from Trypanosoma cruzi (T. cruzi, TcTS) is a crucial enzyme for the survival of this parasite: sialic acids from the host are transferred to the cell surface glycoproteins of the trypanosome, thereby evading the host’s immune system. On the other hand, the sialidase of T. rangeli (TrSA), which shares 70% sequence identity with TcTS, is a strict hydrolase and shows no trans-sialidase activity. Therefore, TcTS and TrSA represent an excellent framework to understand how different catalytic activities can be achieved with extremely similar structures. By means of combined quantum mechanics–molecular mechanics (QM/MM, SCC-DFTB/Amberff99SB) calculations and umbrella sampling simulations, we investigated the hydrolysis mechanisms of TcTS and TrSA and computed the free energy profiles of these reactions. The results, together with our previous computational investigations, are able to explain the catalytic mechanism of sialidases and describe how subtle differences in the active site make TrSA a strict hydrolase and TcTS a more efficient trans-sialidase.Fil: Bueren Calabuig, Juan A.. University of Florida; Estados UnidosFil: Pierdominici Sottile, Gustavo. Universidad Nacional de Quilmes; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Roitberg, Adrián. University of Florida; Estados Unido

Impact of Ser17 phosphorylation on the conformational dynamics of the oncoprotein MDM2

MDM2 is an important oncoprotein that downregulates the activity of the tumor suppressor protein p53 via binding of its N-terminal domain to the p53 transactivation domain. The first 24 residues of the MDM2 N-terminal domain form an intrinsically disordered “lid” region that interconverts on a millisecond time scale between “open” and “closed” states in unliganded MDM2. While the former conformational state is expected to facilitate p53 binding, the latter competes in a pseudo-substrate manner with p53 for its binding site. Phosphorylation of serine 17 in the MDM2 lid region is thought to modulate the equilibrium between “open” and “closed” lid states, but contradictory findings on the favored lid conformational state upon phosphorylation have been reported. Here, the nature of the conformational states of MDM2 pSer17 and Ser17Asp variants was addressed by means of enhanced sampling molecular dynamics simulations. Detailed analyses of the computed lid conformational ensembles indicate that both lid variants stabilize a “closed” state, with respect to wild type. Nevertheless, the nature of the closed-state conformational ensembles differs significantly between the pSer17 and Ser17Asp variants. Thus, care should be applied in the interpretation of biochemical experiments that use phosphomimetic variants to model the effects of phosphorylation on the structure and dynamics of this disordered protein region

From the Molecular Biology to the Gene Therapy of a DNA Repair Syndrome: Fanconi Anemia

Diseases & disorder

Modelado molecular de la interacción de fármacos antitumorales y nucleasas con el ADN

Premio Extraordinario de Doctorado de la UAH en 2013Los métodos computacionales están convirtiéndose en herramientas muy importantes en ciertas áreas de la investigación como la caracterización de sitios de unión de ligandos a proteínas, acoplamiento de pequeñas moléculas en sitios de unión al ADN y proteínas y simulaciones de dinámica molecular. Los resultados obtenidos aportan información que, a veces, está más allá de las posibilidades puramente experimentales y pueden usarse para guiar y mejorar un gran número de experimentos. El objetivo de esta tesis es estudiar mediante técnicas de modelado molecular la interacción entre el ADN y distintos ligandos incluyendo diversos fármacos antitumorales, distintas familias de nucleasas como XPF y la nucleasa de Vibrio vulnificus y la ARN polimerasa II. Las investigaciones se llevaron a cabo en colaboración con distintos grupos experimentales de la Universidad de Alcalá, del grupo del Profesor Egly en el Institut de génétique et de biologie moléculaire et cellulaire de Estrasburgo y de la empresa biotecnológica PharmaMar. Los trabajos realizados se dividen en los siguientes puntos: i)Descripción de la interacción del ADN con el nuevo fármaco antitumoral Zalypsis y análisis de su especificidad de secuencia por técnicas de modelado molecular. ii)Descripción de la interacción del ADN con el nuevo fármaco antitumoral PM01183 y análisis de su especificidad de secuencia por técnicas de modelado molecular. iii)Estudio de la interacción de XPF y la ARN polimerasa II con el ADN. Consecuencias de la incorporación de un aducto covalente con el ADN. iv)Estudio mediante simulaciones de dinámica molecular de la fusión inducida por alta temperatura de un segmento de ADN en ausencia y presencia de fármacos. v)Mecanismo de formación de entrecruzamientos intercatenarios en el ADN por Mitomicina C. Efecto de la modificación de las citosinas en su reactividad. vi)Estudio mediante simulaciones de dinámica molecular del mecanismo de acción de la nucleasa de Vibrio vulnificus e implicaciones en distintas familias de endonucleasas

In vivo imaging of lung inflammation with neutrophil-specific Ga-68 nano-radiotracer

In vivo detection and quantification of inflammation is a major goal in molecular imaging. Furthermore, cell-specific detection of inflammation would be a tremendous advantage in the characterization of many diseases. Here, we show how this goal can be achieved through the synergistic combination of nanotechnology and nuclear imaging. One of the most remarkable features of this hybrid approach is the possibility to tailor the pharmacokinetics of the nanomaterial-incorporated biomolecule and radionuclide. A good example of this approach is the covalent binding of a large amount of a neutrophil-specific, hydrophobic peptide on the surface of Ga-68 core-doped nanoparticles. This new nano-radiotracer has been used for non-invasive in vivo detection of acute inflammation with very high in vivo labelling efficiency, i.e. a large percentage of labelled neutrophils. Furthermore, we demonstrate that the tracer is neutrophil-specific and yields images of neutrophil recruitment of unprecedented quality. Finally, the nano-radiotracer was successfully detected in chronic inflammation in atherosclerosis-prone ApoE(-/-) mice after several weeks on a high-fat diet

XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids

SummaryTrabectedin and Zalypsis are two potent anticancer tetrahydroisoquinoline alkaloids that can form a covalent bond with the amino group of a guanine in selected triplets of DNA duplexes and eventually give rise to double-strand breaks. Using well-defined in vitro and in vivo assays, we show that the resulting DNA adducts stimulate, in a concentration-dependent manner, cleavage by the XPF/ERCC1 nuclease on the strand opposite to that bonded by the drug. They also inhibit RNA synthesis by: (1) preventing binding of transcription factors like Sp1 to DNA, and (2) arresting elongating RNA polymerase II at the same nucleotide position regardless of the strand they are located on. Structural models provide a rationale for these findings and highlight the similarity between this type of DNA modification and an interstrand crosslink

Terapias avanzadas en enfermedades raras

Advanced therapies are a group of medicines for human use based on gene therapy, somatic cell therapy or tissue-engineering. In this paper we present some general basic concepts, describe the most promising strategies and summarize the results of a variety of clinical trials for a significant group of monogenic inherited diseases. Major emphasis is placed on ex vivo gene therapy approaches for diseases of the hematopoietic system, since these corresponded to pioneering treatments that have guided research in this field. We also highlight some examples of successful in vivo gene therapy and point out the contribution of somatic cell therapy and tissue engineering to the group of rare skin diseases. We aim to provide an overview of the state of the art of advanced therapies in rare diseases and highlight some of the cutting-edge technologies under development that can provide more effective and safer treatments in the future.Las terapias avanzadas comprenden un grupo de medicamentos biológicos basados en la terapia génica, la terapia celular y la ingeniería de tejidos. En este artículo se presentan algunos conceptos básicos, se describen las estrategias más prometedoras y se detallan los resultados de diferentes ensayos clínicos para un grupo significativo de enfermedades, especialmente las enfermedades hereditarias monogénicas. Se hace un mayor hincapié en la terapia génica ex vivo en enfermedades del sistema hematopoyético, al ser el grupo de enfermedades pioneras que además han orientado la investigación en el campo. Destacamos también algunos ejemplos de éxito de terapia génica in vivo y señalamos la contribución de la terapia celular y de la ingeniería de tejidos al grupo de enfermedades raras de la piel. Pretendemos con ello dar una visión de la situación de las terapias avanzadas en enfermedades raras y señalamos algunas de las vías de futuro orientadas al desarrollo de tratamientos más eficaces y seguros